Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Engene Holdings Inc (ENGN)

Engene Holdings Inc (ENGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual Meeting Newswire.ca - Thu May 2, 3:05PM CDT

/CNW/ - enGene Holdings Inc. (Nasdaq: ENGN) or ("enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in...

ENGN : 12.67 (-2.39%)
enGene Announces Hiring of Dr. Raj Pruthi as Senior Vice President, Urologic Oncology and Clinical Development Newswire.ca - Tue Apr 9, 7:00AM CDT

/PRNewswire/ - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead...

ENGN : 12.67 (-2.39%)
/C O R R E C T I O N -- enGene Inc./ Newswire.ca - Tue Apr 9, 7:00AM CDT

In the news release, engender Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development, issued 09-Apr-2024 by...

ENGN : 12.67 (-2.39%)
engender Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development Newswire.ca - Tue Apr 9, 7:00AM CDT

/CNW/ - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead product...

ENGN : 12.67 (-2.39%)
enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress Newswire.ca - Mon Mar 11, 3:05PM CDT

/CNW/ - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead product...

ENGN : 12.67 (-2.39%)
enGene To Present at the Leerink Partners Global Biopharma Conference Newswire.ca - Tue Mar 5, 6:00AM CST

/CNW/ - enGene Holdings Inc. (Nasdaq: ENGN) or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in...

ENGN : 12.67 (-2.39%)
enGene Announces Oversubscribed $200 Million Private Placement Financing Newswire.ca - Wed Feb 14, 5:50AM CST

/CNW/ - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a...

ENGN : 12.67 (-2.39%)
enGene Announces Leadership Succession Plan Newswire.ca - Wed Feb 14, 5:45AM CST

/CNW/ - enGene Holdings Inc. (Nasdaq: ENGN) ("enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a...

ENGN : 12.67 (-2.39%)
enGene Appoints Lee Giguere as Chief Legal Officer and Corporate Secretary Newswire.ca - Tue Jan 30, 6:00AM CST

/CNW/ - enGene Holdings Inc. ("enGene," (Nasdaq: ENGN), a clinical-stage genetic medicines company whose lead program is in a pivotal study for...

ENGN : 12.67 (-2.39%)
enGene Reports Full Year 2023 Financial Results and Recent Operational Progress Newswire.ca - Mon Jan 29, 6:00AM CST

Achieved primary and secondary endpoints in Phase 1 portion of LEGEND study in non-muscle invasive bladder cancer (NIMBC); pivotal portion underway with...

ENGN : 12.67 (-2.39%)

Barchart Exclusives

Up 33% YTD, This Energy Dividend Stock Is Still a Top Offshore Pick Barchart - 38 minutes ago
Discover why TechnipFMC has become Barclays' top offshore pick, and how its impressive performance and strategic advantages make it a standout dividend stock. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot